NCT05102240 Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer
| NCT ID | NCT05102240 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tata Memorial Hospital |
| Condition | Cervix Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,800 participants |
| Start Date | 2022-02-24 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,800 participants in total. It began in 2022-02-24 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability Hypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.
Eligibility Criteria
Inclusion Criteria: For Aim 1 and Aim 3: * Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI/CT images at the time of diagnosis and brachytherapy For Aim 2 * Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT. Exclusion Criteria: 1. Lack of disease or toxicity outcomes. 2. Lack of images in the hospital database.
Contact & Investigator
Supriya Sastri (nee Chopra), MD
PRINCIPAL INVESTIGATOR
Tata Memorial Centre, The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
Frequently Asked Questions
Who can join the NCT05102240 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 90 Years, studying Cervix Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05102240 currently recruiting?
Yes, NCT05102240 is actively recruiting participants. Contact the research team at supriyasastri@gmail.com for enrollment information.
Where is the NCT05102240 trial being conducted?
This trial is being conducted at Navi Mumbai, India.
Who is sponsoring the NCT05102240 clinical trial?
NCT05102240 is sponsored by Tata Memorial Hospital. The principal investigator is Supriya Sastri (nee Chopra), MD at Tata Memorial Centre, The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC). The trial plans to enroll 1,800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.